Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen.

BACKGROUND Conventional biopsy fails to detect the presence of some prostate cancers (PCas). Men with a prior negative biopsy but persistently elevated prostate-specific antigen (PSA) pose a diagnostic dilemma, as some harbor elusive cancer. OBJECTIVE To determine whether use of magnetic resonance-ultrasound (MR-US) fusion biopsy results in improved detection of PCa compared to repeat conventional biopsy. DESIGN, SETTING, AND PARTICIPANTS In a consecutive-case series, 105 subjects with prior negative biopsy and elevated PSA values underwent multiparametric magnetic resonance imaging (MRI) and fusion biopsy in an outpatient setting. INTERVENTION Suspicious areas on multiparametric MRI were delineated and graded by a radiologist; MR-US fusion biopsy was performed by a urologist using the Artemis device; targeted and systematic biopsies were obtained regardless of MRI result. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS Detection rates of all PCa and clinically significant PCa (Gleason ≥3+4 or Gleason 6 with maximal cancer core length ≥4 mm) were determined. The yield of targeted biopsy was compared to systematic biopsy. The ability of an MRI grading system to predict clinically significant cancer was investigated. Stepwise multivariate logistic regression analysis was performed to determine predictors of significant cancer on biopsy. RESULTS AND LIMITATIONS Fusion biopsy revealed PCa in 36 of 105 men (34%; 95% confidence interval [CI], 25-45). Seventy-two percent of men with PCa had clinically significant disease; 21 of 23 men (91%) with PCa on targeted biopsy had significant cancer compared to 15 of 28 (54%) with systematic biopsy. Degree of suspicion on MRI was the most powerful predictor of significant cancer on multivariate analysis. Twelve of 14 (86%) subjects with a highly suspicious MRI target were diagnosed with clinically significant cancer. CONCLUSIONS MR-US fusion biopsy provides improved detection of PCa in men with prior negative biopsies and elevated PSA values. Most cancers found were clinically significant.

[1]  Heinz-Peter Schlemmer,et al.  MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. , 2006, European urology.

[2]  A. Haese*,et al.  High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. , 2006, European urology.

[3]  P. Mozer,et al.  Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. , 2012, European urology.

[4]  W. Ellis,et al.  Improved prostate cancer detection with anterior apical prostate biopsies. , 2006, Urologic oncology.

[5]  Pingkun Yan,et al.  Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. , 2011, The Journal of urology.

[6]  William J Catalona,et al.  Serial biopsy results in prostate cancer screening study. , 2002, The Journal of urology.

[7]  Roberto Passariello,et al.  Value of Magnetic Resonance Spectroscopy Imaging and Dynamic Contrast-Enhanced Imaging for Detecting Prostate Cancer Foci in Men With Prior Negative Biopsy , 2010, Clinical Cancer Research.

[8]  J. Fütterer,et al.  Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. , 2013, European urology.

[9]  M. Barry,et al.  Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era. , 2007, Journal of the National Cancer Institute.

[10]  P. Puppo.  Repeated negative prostate biopsies with persistently elevated or rising PSA: a modern urologic dilemma. , 2007, European urology.

[11]  Robert W Veltri,et al.  Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study. , 2003, The Journal of urology.

[12]  Case records of the Massachusetts General Hospital. Case 9-2012. A 67-year-old man with a persistently elevated PSA level. , 2012, The New England journal of medicine.

[13]  Yipeng Hu,et al.  Characterizing clinically significant prostate cancer using template prostate mapping biopsy. , 2011, The Journal of urology.

[14]  Baris Turkbey,et al.  Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. , 2012, The Journal of urology.

[15]  K. Fareed,et al.  Office based transrectal saturation biopsy improves prostate cancer detection compared to extended biopsy in the repeat biopsy population. , 2011, The Journal of urology.

[16]  C C Schulman,et al.  Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? , 2001, The Journal of urology.

[17]  Thomas Hambrock,et al.  Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. , 2012, European urology.

[18]  Aaron Fenster,et al.  Clinical application of a 3D ultrasound-guided prostate biopsy system. , 2011, Urologic oncology.

[19]  Georgios Sakas,et al.  A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion. , 2011, The Journal of urology.

[20]  K. Wallner,et al.  The morbidity of transperineal template‐guided prostate mapping biopsy , 2008, BJU international.

[21]  K. Wallner,et al.  Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting , 2009, Prostate Cancer and Prostatic Diseases.

[22]  Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. , 2007, European urology.

[23]  Monish Aron,et al.  3-Dimensional elastic registration system of prostate biopsy location by real-time 3-dimensional transrectal ultrasound guidance with magnetic resonance/transrectal ultrasound image fusion. , 2012, The Journal of urology.

[24]  Mark Emberton,et al.  Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. , 2013, European urology.

[25]  M. Melamed,et al.  Identifying candidates for active surveillance: an evaluation of the repeat biopsy strategy for men with favorable risk prostate cancer. , 2012, The Journal of urology.

[26]  Shyam Natarajan,et al.  Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. , 2013, The Journal of urology.

[27]  Baris Turkbey,et al.  Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. , 2011, The Journal of urology.

[28]  Ralph Strecker,et al.  Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding--multiparametric MR imaging for detection and biopsy planning. , 2011, Radiology.

[29]  M. Terris,et al.  Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. , 1989, The Journal of urology.

[30]  Amy Blase,et al.  PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. , 2007, Urology.